James R. Bischoff

Roche (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index8.1kcitations117works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(24), Prostate Cancer Treatment and Research(22), Computational Drug Discovery Methods(18), Cancer, Lipids, and Metabolism(18), Protein Kinase Regulation and GTPase Signaling(17)

Publications117 total

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors
Frontiers in Immunology·2024· 3 citedOpen Access
Supplementary Data 5 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 4 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Data from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 3 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 7 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 2 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 1 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 6 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 2 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 6 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 5 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 8 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 3 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 1 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 8 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Data from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 4 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data 7 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Joaquı́n Pastor(13), Julen Oyarzábal(10), María I. Albarrán(10), Sonia Martı́nez(9), Carmen Blanco‐Aparicio(9), Obdulia Rabal(8), Jesús Fominaya(7), Ana Isabel Hernández(7), David Beach(6), Paolo Pevarello(6), Wolfgang Link(6), Antonio Cebriá(6), Patricia Alfonso(6), David Cebrián(6), Miguel Á. Piris(5), Milagros Lorenzo(5), Carmen Varela(5), Margarita Sánchez‐Beato(4), Teresa G. Granda(4), Gilles Bignan(4)